New obesity drug HRS-7535 put through drug interaction tests

NCT ID NCT07269756

Completed Knowledge-focused Sponsor: Shandong Suncadia Medicine Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 30, 2026 · Updated 3 times

Summary

This Phase 1 study in 40 overweight or obese adults examined how a new drug called HRS-7535 interacts with four common medications: acetaminophen (pain reliever), digoxin (heart medication), rosuvastatin (cholesterol drug), and omeprazole (acid reflux treatment). Participants took HRS-7535 alone and then with each other drug to measure changes in drug levels in the blood. The goal was to see if dose adjustments are needed when combining these medicines.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: HRS-7535
What this could lead to: If successful, this study could help determine safe dosing of HRS-7535 with other common medications for obesity treatment.
What could go wrong: This is an early Phase 1 study with only 40 participants, focused on drug interactions rather than weight loss. Results may not predict real-world effects or safety.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OBESITY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder Overweight

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OBESITY OVERWEIGHT

Contacts and locations

Locations

Suzhou Municipal Hospital

Suzhou, Jiangsu, 215000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.